Scribe Therapeutics Q3 revenue falls to $1.64M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Scribe Therapeutics, Inc. (SCTX) reported third-quarter 2026 collaboration revenue of $1.636 million, compared with $20.113 million in the year-earlier quarter, and a net loss of $9.863 million ($0.68 per basic and diluted share), versus net income of $1.472 million. Research and development expense was $8.259 million versus $14.421 million; general and administrative expense was $4.239 million versus $3.531 million. Cash, cash equivalents and marketable securities were $174.230 million at September 30, 2026. Under its current operating plan, Scribe believes these funds will cover operating expenses and capital expenditures into the first half of 2029.
The Phase 1 trial of STX-1150 is ongoing, with initial data expected in the first half of 2027. In non-human primates, a single 0.75 mg/kg administration produced LDL-C reductions greater than 50% sustained for two years, with liver enzyme profiles comparable to saline controls; STX-1200 surrogates achieved greater than 95% Lp(a) reduction. Scribe also expanded its multi-year Sanofi collaboration to include its ELXR epigenetic silencing technology.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway is expected into the first half of 2029.
Negative
- Moderate pointCollaboration revenue was $1.636 million, down from $20.113 million in Q3 2025.
- Moderate pointQuarterly net result shifted from $1.472 million income to a $9.863 million loss.
Filing Explained
Scribe reports its IPO, the underwriters’ full option exercise and concurrent Sanofi private placement raised approximately
8-K Event Classification
Key Figures
Key Terms
Epigenetic Long-term X Repressor (ELXR) technical
low-density lipoprotein cholesterol (LDL-C) medical
PCSK9 medical
lipoprotein(a) (Lp(a)) medical
atherosclerotic cardiovascular disease (ASCVD) medical
X-Editor (XE) technical
Earnings Snapshot
Based on its current operating plan, Scribe believes cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were SCTX's third-quarter 2026 financial results?
When does Scribe expect initial STX-1150 Phase 1 data?
What did Scribe report about STX-1150 in non-human primates?
What changed in Scribe's Sanofi collaboration?
AI-generated analysis. How Rhea-AI works. Not financial advice.
